Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe^® in patients with asthma: the real-world EVOLVE study.

ABSTRACT:

Background

Inhalation therapy with corticosteroids and long-acting β₂-agonists has been the mainstay of asthma management. However, choosing the correct inhaler technique is essential to effectively deliver the medication to the lungs to attain good asthma control.

Objective

This study aimed to evaluate asthma control and device usability with salmeterol/fluticasone fixed-dose combination (FDC) administered through Synchrobreathe^®, a breath-actuated inhaler (BAI), in Indian patients with persistent asthma (EVOLVE study).

Design

The present study was a prospective, open-label, non-comparative, multi-center, observational study.

Methods

The study enrolled 490 patients with documented diagnoses of asthma who were treatment-naive or uncontroll

SUBMITTER: Balamurugan S 

PROVIDER: S-EPMC9761246 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature